New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2013
14:31 EDTAKRXAkorn sees FY13 adjusted EPS 57c-61c, consensus 66c
Sees FY13 revenue $325M-$335M, consensus $330.73M. The company's guidance excludes the impact from any products for which the company has not yet received FDA approval.
News For AKRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
13:05 EDTAKRXAkorn price target raised to $60 from $50 at Guggenheim
Guggenheim raised Buy rated Akron's price target to $60 from $50 following the Q4 report. The analyst believes Akorn is well positioned for upward earnings revisions that will drive shares higher in 2015.
07:17 EDTAKRXAkorn sees Q1 revenue down sequentially from Q4
Q1 revenue consensus $217.62M. The company said: "Based on several previously disclosed factors contributing to Q4 performance including higher-than-normal in-transit revenue at the end of the Q3, seasonality in the Hi-Tech Pharmacal cough and cold business and the successful resolution of backorders from the third quarter encountered due to clobetasol market dynamics, the company believes 1Q15 revenue will be below 4Q14 revenue. Akorn projects that consolidated net revenue will increase sequentially throughout 2015 due to a combination of seasonality in the business and the cumulative impact of new launches on quarterly revenue throughout the year."
07:14 EDTAKRXAkorn sees FY15 adjusted EPS $1.88-$1.98, consensus $1.82
Subscribe for More Information
07:12 EDTAKRXAkorn reports Q4 adjusted EPS 50c, consensus 45c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use